Belen Garijo
Chief Executive Officer
2026 – Present
0 years (current)
Key Decisions & Impact
Taking complete, aggressive control during a critical strategic transition, Belen Garijo accelerated the 'Play to Win' immunology pivot. She finalized the complex, controversial divestiture of the Consumer Healthcare division (Opella), reallocating billions in capital entirely toward high-risk, high-reward biological R&D. Furthermore, she violently pushed AI-driven drug discovery partnerships to modernize the traditionally sluggish French research engine.
Legacy
Garijo's defining mandate is strictly executing the final, painful transformation of Sanofi into a pure-play, science-led biotechnology titan. By heavily prioritizing specialty care execution over diversified mass-market stability, she risks the entire empire to secure its long-term lucrative future. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. This ensures future stability. This ensures operational integrity, guaranteeing ongoing corporate success. Yes.